**Distinct Subpopulations of Head and Neck Cancer Cells with Different Levels of Intracellular Reactive Oxygen Species Exhibit Diverse Stemness, Proliferation, and Chemosensitivity**

Ching-Wen Chang¹, Yu-Syuan Chen¹, Shiu-Huey Chou², Chia-Li Han³, Yu-Ju Chen³, Cheng-Chieh Yang⁴, Chih-Yang Huang¹,⁶,⁷, and Jeng-Fan Lo¹,⁴,⁵,⁸,⁹,¹⁰

**Abstract**

Head and neck squamous cell carcinoma (HNSCC) is driven by cancer-initiating cells (CIC), but their maintenance mechanisms are obscure. For hematopoietic stem cells, low levels of intracellular reactive oxygen species (ROS\(^{\text{Low}}\)) is known to help sustain stemness properties. In this report, we evaluated the hypothesis that ROS\(^{\text{Low}}\) character conferred CIC properties in HNSCC. Sphere cultures define CIC in HNSCC cell populations (HN-CIC). We found that ROS\(^{\text{Low}}\) cells in HN-CIC defined in this manner were more numerous than in parental HNSCC cells. Further, ROS\(^{\text{Low}}\) cells frequently coexpressed CIC surface markers such as memGrp78 and Glut3. Exploiting flow cytometry to sort cells on the basis of their ROS level, we found that isolated ROS\(^{\text{Low}}\) cells displayed relatively more CIC properties, including quiescence, chemoresistance, in vitro malignant properties, and tumorigenicity. Pharmacological depletion of ROS modulators in cisplatin-treated HN-CIC reduced CIC properties, enhancing cell differentiation and enhancing cisplatin-induced cell death. Overall, our work defined cell subpopulations in HNSCC on the basis of differential intracellular ROS levels, which associated with stemness and chemoresistance properties. On the basis of our findings, we suggest that strategies to promote intracellular ROS levels may heighten the efficacy of conventional chemotherapy used for HNSCC treatment. *Cancer Res; 74(21); 6291-305. ©2014 AACR.*

**Introduction**

Emerging evidence supports the hierarchical model of cancer-initiating cells [CIC; also referred to as cancer stem cells (CSC)], in that, each tumor formation is generated from a distinct subset of cells with characteristics of self-renewal and differentiation capacity (1). Clinically, conventional chemotherapeutics generally affect proliferative cells, potentially eliminating proliferating cancer cells but do not target slow dividing cells (2). Like normal tissue stem cells, CICs also exhibit quiescent slow-cycling phenotype (3). In addition, CICs have been shown to be involved in tumor progression, cancer recurrence, and metastasis because of their therapeutic resistance (4, 5). Therefore, to uncover the regulatory physiologic mechanisms that sustain the slow-growing CICs warrants an important study for future therapy development.

Head and neck squamous cell carcinoma (HNSCC) ranks the sixth most common cancer worldwide (6). Previously, we have enriched and identified the existence of a subpopulation of head and neck CICs (HN-CIC) from sphere cells. The enriched HN-CICs from HNSCC cells display both the enhanced properties of stemness and malignancy (7). In addition, the cell surface markers such as CD133 (8) and cell membrane anchoring GRP78 (ref. 9) for identifying the HN-CICs have also been reported in our previous studies. However, the unique physiology and regulatory mechanisms that mediate the HN-CIC properties of clinical retraction remain elusive. Therefore, the studies on targeting the mechanism(s) in
HN-CICs to contribute to the therapeutic resistance of HNSCC would benefit future HNSCC therapy.

Reactive oxygen species (ROS), including superoxide (O$_2^-$), hydrogen peroxide (H$_2$O$_2$), and the hydroxyl radical (HO$^\cdot$), play a major role to cellular proliferation, differentiation, and survival (10). It has recently been shown that stem cells have a unique mechanism, which is important to cope with the accumulated ROS, to increase antioxidant defenses and to play a crucial redox regulator on self-renewal and differentiation, (11–13). For instance, hematopoietic stem cells maintain a low intracellular ROS status that in turn facilitates quiescence, whereas a higher ROS state activates cell proliferation and differentiation but exhausts self-renewal in these cells (14). Achuthan and colleagues (15) demonstrate that drug-induced senescence generates chemoresistant stem-like cells with low ROS in breast cancer. In addition, a lower level of intracellular ROS is also present in breast CSCs, which may contribute to radioresistance (16). Overall, these studies have led to the hypothesis that the maintenance of low ROS levels within the CICs is important for regulating chemoresistance and quiescent state.

Cancer cells are capable of maintained at an oxidation-reduction reactions (redox) homeostasis state by upregulating ROS-scavenging enzymes, which can confer drug resistance (17). Superoxide dismutase (SOD), catalase, glutathione peroxidase, and peroxiredoxin are major intracellular ROS-scavenging enzymes (17). Furthermore, accumulating evidence supports that elevated activity of SOD and catalase is associated with promoting cancer cell resistance to anticancer agents (15, 18, 19).

In this study, we determined the tumorigenic potential and stemness properties of subpopulation cells with the differential intracellular level of ROS in HNSCCs and HN-CICs. We showed that the HN-CICs possessed more ROS$^{\text{Low}}$ cells than HNSCCs did. Then, we demonstrated the cells of low level of ROS highly coexpressed the stem cell markers (CD133, memGrp78, and Glut3) and the subpopulation of ROS$^{\text{Low}}$ cells was expanded in ALDH$^+$ cells than in ALDH$^-$ cells. Furthermore, three types of cells with differential level of ROS: high, middle, and low level of ROS (termed $\text{ROS}^{\text{High}}$, $\text{ROS}^{\text{Medi}}$, and $\text{ROS}^{\text{Low}}$) were isolated, respectively. The isolated ROS$^{\text{Low}}$ cells displayed CIC properties and possessed high tumorigenicity. Lower ROS level in CICs was also associated with chemoresistance, and pharmacologic depletion of ROS scavengers enhanced the chemosensitivity but diminished the clonogenicity of HN-CICs. In summary, our studies suggest that distinct subpopulation of cells with differential ROS level exerted diverse stemness properties, chemoresistance, and tumorigenicity in HNSCC, and eliminating ROS$^{\text{Low}}$ cells should be considered for further exploration on therapeutic development for HNSCC.

Together, abrogation of drug-resistant mechanisms by depletion of ROS scavengers in CICs could have significant therapeutic implications in the future.

Materials and Methods

Cell lines

Human HNSCC cell lines, tongue carcinoma cells (SAS), obtained from the Japanese Collection of Research Biore- sources (20) were cultured in DMEM medium with 10% FBS. Human gingival squamous carcinoma cells (OECM-1) were provided from Dr. C.L. Meng (National Defense Medical College, Taipei, Taiwan) and grown in RPMI supplemented with 10% FBS. Cells were cultured at 37°C containing 5% CO$_2$.

Establishment of the primary cells from patients with HNSCC

This research follows the tenets of the Declaration of Helsinki and all samples were obtained after informed consent from the patients. The clinical samples were approved and in accordance with the Institutional Review Board (IRB no., 2012-07-035BCY), Taipei Veterans General Hospital. Primary HN-CICs were established from patients with HNSCC that derived from specimens of oral surgical resection. The primary HN-CICs were cultured in serum-free DMEM/F12 medium (GIBCO), N2 supplement (GIBCO), 10 ng/mL EGF, and 10 ng/mL human recombinant basic fibroblast growth factor-basic (bFGF; R&D Systems). Otherwise, the primary HNSCCs were cultured in RPMI supplemented with 10% FBS.

Cell lines cultivation and enrichment of HN-CICs

The two cell lines SAS and OECM1 were plated at a density of 7.5 $\times$ 10$^3$ live cells per 10-mm dish, then cultured in tumor sphere medium consisting of serum-free DMEM/F12 medium (GIBCO), N2 supplement (GIBCO), 10 ng/mL human recombinant bFGF-basic, and 10 ng/mL EGF (R&D Systems). The medium was changed every other day until the tumor sphere formation was achieved to enrich the SAS-HN-CICs or OECM1-HN-CICs in about 4 weeks (7).

Establishment of cisplatin-resistant cell line

The cisplatin-resistant (SAS-cisPt$^R$) cells were generated by serially fractionated exposure of the parental SAS cell lines to cisplatin over a time period of 3 months. At 5 $\mu$mol/L of cisplatin killed more than 50% of cells for 48 hours, cells were allowed to recover over 20 days with fresh medium and repeated three times. The cisplatin-resistant (SAS-cisPt$^R$) cells were for further experiments (Supplementary Fig. S1).

Cell viability and chemoresistance assay

Cells were seeded onto 24-well culture plates at 1 $\times$ 10$^4$ cells per well for 24 hours. Then the test drugs were added to the culture medium for 72 hours. Subsequently, 5 $\mu$L of MTT solution (4 mg MTT/ml PBS) was added to each well and the cells were further incubated at 37°C for 3 hours until a purple formazan was visible. The staining solution was removed and 100 $\mu$L DMSO was added at room temperature in the dark for 30 minutes. The absorbance of DMSO solution was detected with a microtiter plate reader at 560 nm. The cell viability ratio is calculated as OD$560$ of experimental groups/OD$560$ of control groups.

ROS assay and cell sorting

To detect the intracellular ROS levels, single-cell suspension was resuspended in PBS contain 2% FBS at 1$^0$ cells/mL, and
stained with 10 μmol/L DCF-DA, 5 μmol/L CM-H2DCFDA, 2.5 μmol/L CellROX Deep Red, or 5 μmol/L Carboxy-DCFDA (Invitrogen) at 37°C for 30 minutes, respectively. Cells were washed and resuspended in 10 μmol/L propidium iodide (PI) solution for analysis or sorting by using FACSaria cell sorter (Becton Dickinson). For all FACS experiments, the dead cells were excluded by PI staining.

**Anchorage-independent growth assay**

Each well (35 mm) of a 6-well culture dish was coated with 2 mL bottom agar (Sigma-Aldrich) mixture [DMEM, 10% (v/v) FBS, 0.6% (w/v) agar]. After the bottom layer was solidified, sorted cells were cultured in 2 mL top agar medium mixture [DMEM, 10% (v/v) FBS, 0.3% (w/v) agar], and the dishes were incubated for 2 weeks at 37°C. Subsequently, plates were stained with 0.005% Crystal Violet then the colonies were counted. The number of total colonies was counted over five fields per well for a total of 15 fields in triplicate experiments.

**In vivo tumorigenic assay**

All animal studies were approved and in accordance with the Institutional Animal Care and Use Committee (IACUC) of National Yang-Ming University (Taipei, Taiwan; IACUC approval no., 1001223). Equal volume of cells and Matrigel (BD Biosciences) were mixed and s.c. injected into the back of nude mice (6–8 weeks). Tumor volume was calculated using the following formula: (Length × Width²)/2.

**Results**

**Quantification of intracellular ROS level and coexpression of CIC surface markers in parental HNSCCs cells, sphere cells, and primary cells established from HNSCC tumor tissue**

It has been demonstrated that cells with low intracellular ROS concentration are more likely to maintain their stem properties in hematopoietic stem cells (14). In addition, the association of low ROS level and radioresistance in breast CSCs has been reported (16). Previously, we have successfully enriched a subpopulation of HN-CICs derived from both SAS and OECM1 HNSCCs (7, 9). Herein, we first aim to understand whether the intracellular level of ROS is relatively lower in HN-CICs. To measure the intracellular ROS level of HN-CICs, the cells were stained with oxidation sensitive fluorescent probe (DCFDA, CM-DCFDA, or CellROX Deep Red, respectively) followed by flow-cytometry analysis (14, 16). Compared with parental HNSCCs, we observed that a subpopulation of cells with low intracellular level of ROS was significantly increased in HN-CICs (for both SAS-S and OECM1-S; Fig. 1A and B and Supplementary Fig. S2A). In addition, primary cells (primary-S) freshly established from HNSCC patient tumor tissue grown in defined serum-free medium with bFGF and EGF growth factors (the medium to grow the SAS-S and OECM1-S cells) also displayed more cells with low ROS content in comparison with the same cells cultivated in medium supplied with 10% FBS (primary-P; the medium to grow the SAS-P and OECM1-P cells; primary-S, 12.2% vs. primary-P, 4.3%; Fig. 1A). We next sought to determine whether the fluorescence change were attributable to be altered by the dye oxidation and not altered by uptake, ester cleavage, or efflux of the probe. As shown in Supplementary Fig. S2B, these results demonstrated that no significant difference of SAS-P and SAS-S cells on staining of the oxidation-insensitive analog of Carboxy-DCFDA as the negative control (Supplementary Fig. S2B; ref. 21).

Our previous data demonstrate that both memGRP78 and CD133 could be used as a surface marker for enrichment of HN-CICs (8, 9). Next, we wanted to determine whether there was a positive correlation between the lower level of ROS and the abovementioned CIC surface markers of HN-CICs. Examined by FACS analyses, the HN-CICs showed elevated coexpression of either memGRP78 or CD133 with lower level of ROS in comparison with the parental HNSCCs (Fig. 1C and D). Furthermore, the expression of Glut3, a recently identified cell surface marker of brain tumor stem cells (22), was also highly correlated with the cells containing low intracellular ROS amount (Fig. 1E). Finally, it has been shown that cells harboring higher aldehyde dehydrogenase (ALDH) activity display the characteristics of CSCs (23). As expected, the sorted ALDH⁺ cells also displayed more low ROS cells than the sorted ALDH⁻ cells in HNSCCs (Fig. 1F). To further clarify the correlation between ALDH activity and representative CIC markers of cells, SAS sphere cells or cisplatin-resistant SAS cells (SAS-cisPtR) were selectively double stained with CD133/Glut3 or Grp78/Glut3. The ALDH activity of the double-stained cells was also examined by ALDEFLUOR assay. Interestingly, we found that cell subpopulation positively double stained with the selected CIC markers (such as the CD133⁺/Glut3⁻ or memGRP78⁺/Glut3⁻ subpopulation) also contained the highest level of ALDH activity in comparison with the rest individual subpopulations (Supplementary Fig. S1). The abovementioned observation suggests that the ALDH⁺ subpopulation cells mainly overlap with the same subpopulation of cells that are Grp78⁻/CD133⁺ Glut3⁻ in HNSCC cells. Collectively, these results suggest that lower level of ROS is closely related to cancer stemness properties in HN-CICs.

Interestingly, we also observed a subpopulation of cells containing higher level of endogenous ROS in HN-CICs (Fig. 1G). The high ROS level may be reflective of an “activated” state to mimic the proliferative activity of progenitor cells in neural stem cells (24). Characterization of the ROSHigh cells was further examined (see text later).

**ROSLow cells display CIC properties**

To characterize the CIC properties of cells with differential level of intracellular ROS amount, we stained the HN-CICs with ROS-indicator dye DCFDA to separate cells into ROSLow, ROSMedium, and ROSHigh subpopulations followed by flow cytometry (Fig. 2A), and the stemness properties of the three isolated cell subpopulations were further assessed. Initially, we observed that the ROSHigh cells maintained a spheroid-growing phenotype; however, both the ROSMedium and ROSHigh cells...
cells grew as an adherent phenotype under the cell culture condition containing 10% FBS (Fig. 2B). Furthermore, the freshly isolated ROSLow, ROSMedi, and ROSHigh cells were cultivated within the medium containing 10% FBS for 5 days; afterward, the intracellular ROS level of the cultivated cells was analyzed, respectively. We observed that the ROSLow cells remained as ROSLow cells, whereas cells with a low level of ROS were not detectable from the further cultivated ROSMedi and ROSHigh subpopulation cells by FACS analyses (Fig. 2C).

In addition, the expression level of stemness genes (Oct4 and Nanog) within the ROSLow, ROSMedi, and ROSHigh cells was examined transcriptionally and translationally. As shown in Fig. 3A and B, we observed enhanced expression of mRNA transcript and protein level of stemness genes (Oct4 and Nanog) in ROSLow cells in comparison with those of ROSMedi and ROSHigh cells, respectively. Next, we performed tumor spheres formation assay for evaluating the self-renewal ability of ROSLow, ROSMedi, and ROSHigh cells. Again, the ROSLow cells...
displayed better sphere-forming capability than ROS<sub>Medi</sub> and ROS<sub>High</sub> cells did (Fig. 3C). Of note, the ROS<sub>High</sub> cells displayed an intermediate sphere-forming ability (Fig. 3C and Supplementary Fig. S3A).

In reference to stem cell phenotype, stem cell can be further identified by property of smaller cell size (25–27). Additional evidence also suggests that terminally differentiated keratinocytes progressively increase their cell size during human...
keratinocyte maturation (28). We therefore analyzed cell size of $R_{\text{OSLow}}$, $R_{\text{OSMedi}}$, and $R_{\text{OSHigh}}$ cells by physical parameters forward and side scatter (FSC, cell size and SSC, cell granularity). As shown in Fig. 3D, the size of $R_{\text{OSLow}}$ cells was smaller than that of $R_{\text{OSMedi}}$ and $R_{\text{OSHigh}}$ cells.

A low endogenous ROS status of HNSCCs maintains the quiescent state of CICs

Stem cells are present in a quiescent state but are able to exit quiescence by ROS activation; in addition, the quiescent state appears to be necessary for retaining the self-renewal of stem cells, and is a critical factor in the resistance of CICs to chemotherapy and targeted therapies (29). Next, we sought to determine whether the sorted $R_{\text{OSLow}}$ cells possess the abovementioned stem cell perspectives. To assess the quiescent state of cells, we performed cell-cycle analysis by double staining the cells with proliferative marker Ki-67 and PI for DNA content. As expected, we found that the sorted $R_{\text{OSLow}}$ cells were present in a relatively quiescent state (Ki-67$^-$/PI$^-$, 2.5%), whereas the sorted $R_{\text{OSHigh}}$ cells displayed the highest percentage of proliferative activity (Ki-67$^-$/PI$^-$, 49.5%; Fig. 3E). The above observation was further confirmed by immunoblotting with the cell-cycle exit index [BrdUrd (bromodeoxyuridine) and Ki67]. As shown in Fig. 3F, we discovered that the sphere cells expressing high oxidative state (yellow arrows) exhibited a significantly higher proliferative activity in comparison with the cells expressing lower oxidative state (white arrows). We next sought to determine whether increasing of intracellular superoxide level by NADPH oxidase activation could trigger cell-cycle entry of the quiescent $R_{\text{OSLow}}$ cells, which were largely resided in sphere cells? Strikingly, the sphere cells treated with NADPH oxidase activator H2O2 (30) or arsenic (31) displayed more adhesive cells but less sphere cells under microscopic observation (Supplementary Fig. S3B). These data indicate that the low ROS state is associated with the quiescent state of stem cells; on the contrary, the high ROS state is correlated with proliferative activity in HNSCCs.

$R_{\text{OSLow}}$ cells show enhanced malignant potentials in vitro and in vivo

To evaluate the differential malignancy among $R_{\text{OSLow}}$, $R_{\text{OSMedi}}$, and $R_{\text{OSHigh}}$ cells, the in vitro anchorage-independent growth ability and the in vivo xenografts assay were performed. The sorted $R_{\text{OSLow}}$ cells significantly grew larger and more colonies than the $R_{\text{OSMedi}}$ cells and $R_{\text{OSHigh}}$ cells did in soft agar (Fig. 4A). In vivo, the $R_{\text{OSLow}}$ cells also showed the best tumor-initiating ability, being able to form tumor with only 500 inoculated cells, whereas the $R_{\text{OSHigh}}$ cells needed at least 10⁴ cells to grow the tumors, which concludes that the $R_{\text{OSLow}}$ cell is 20-fold more tumorigenic than the $R_{\text{OSHigh}}$ cells. Nevertheless, the $R_{\text{OSMedi}}$ cells did not generate any tumors under the examined conditions (from 5 × 10¹ to 1 × 10⁴ cells, Fig. 4B and C).

To further verify the hypothesis that low level of ROS is pivotal for maintenance of cancer stemness properties and responsible for tumor growth in nude mice, we treated the cells with cisplatin for 72 hours, both the parental SAS and OECM1 cells gave an IC₅₀ value of around 7.5 μmol/L; however, the SAS sphere cells or OECM1 sphere cells showed a similar IC₅₀ value of more than 20 μmol/L to the cisplatin treatment (Fig. 5A). Furthermore, the SAS sphere cells displayed an enhancement of $R_{\text{OSLow}}$ cells in a dose-dependent manner under cisplatin treatment (Fig. 5B). In addition, we found an approximately 4-fold reduction in the percentage of $R_{\text{OSHigh}}$ cells in the cisplatin treatment group versus the untreated group (Fig. 5C; untreated: 20% vs. cisplatin treated: 5%), suggesting that $R_{\text{OSHigh}}$ cells are relatively chemosensitive in comparison with $R_{\text{OSLow}}$ cells, in SAS sphere cells.

Cancer stem properties are enhanced during the selection of cisplatin resistance in HNSCC (32). To further evaluate the...
A

B

C

D

E

F

Chang et al.
correlation between low ROS level and cancer stemness properties, we established a cisplatin-resistant HNSCC cell line (SAS-cisPtR) from SAS cells by progressive cisplatin treatment (Supplementary Fig. S4; and see details from Materials and Methods). Obviously, the cell subpopulation with low level of ROS was significantly enhanced in cisplatin-resistant HNSCCs (SAS-cisPtR; Fig. 5D). It has also been shown that cells harboring higher ALDH activity display the characteristics of CSCs (23). Therefore, we wanted to understand the relationship between ALDH activity and cisplatin resistance in HNSCCs. Empirically, we found that SAS-cisPtR cells increased the percentage of ALDH-positive (ALDH+) cells (Fig. 5E).

**ROS scavenging and pharmacologic modulation of ROS level affect the chemosensitivity of HN-CICs**

In light of recent findings that conventional chemotherapy may not be in sufficient effect, in which the increased expression of ROS defense genes is accompanied within CICs (16, 33, 34). Given our observations of HN-CICs containing more ROSLow cells, we proposed that these cells may possess elevated level of ROS-scavenging enzymes compared with HNSCCs. Therefore, we compared the expression profile of ROS scavenger genes of the enriched HN-CICs from ROSLow (from SAS to OECM1) with that of parental cells (SAS and OECM1) by Affymetrix microarray analyses. As noticed, the transcripts of some ROS scavenger genes were upregulated in enriched HN-CICs (Fig. 5F and Supplementary Fig. S5). Furthermore, this Affymetrix microarray analysis showed significant increasing trend of superoxide dismutase 2 (SOD2), catalase (CAT), and peroxiredoxin 3 (PRDX3) in the enriched HN-CICs (Fig. 5F). Both SOD2 and CAT are antioxidant enzymes, and are associated with regulation of cellular ROS and the acquired drug resistance in cancer (15, 17, 35). Consistent with microarray results, RT-PCR analyses showed that the expression of SOD2 and CAT transcript was increased in enriched HN-CICs than that in parental HNSCCs (Fig. 5G). Furthermore, the catalase enzymatic activity of HNSCC and HN-CICs was measured by catalase activity assay. As shown in Supplementary Fig. S6, HN-CICs exhibited a higher catalase activity as compared with HNNSCC. However, we did not see significant difference of the PRDX3 transcript among the HN-CICs and HNSCCs (Fig. 5G). We observed that low ROS level was in association with upregulation of antioxidant enzymes such as SOD2 and CAT in HN-CICs (Fig. 5G). Next, we aimed to pharmacologically inhibit or genetically diminish the activity of ROS scavenger enzymes, then to abrogate the chemoresistance and stemness properties of CICs. Pharmacologic and genetic inhibition of SOD2 or catalase, respectively, both reduced the ROSLow subpopulation cells in SAS sphere cells (Fig. 5H; around 8%; Supplementary Fig. S7A and S8A). In opposite, single cisplatin treatment enhanced the ROSLow cell subpopulation in HN-CICs (Fig. 5H; 22% and Supplementary Fig. S7A). However, combined treatment with cisplatin plus 2-methoxyestradiol (2-ME) or 3-amino-1,2,4-triazole (3AT) significantly lowered the ROSLow cell subpopulation compared with single treatment with cisplatin in HN-CICs (Fig. 5H; and Supplementary Fig. S7A). Furthermore, triple treatment with 2-ME, 3-AT plus cisplatin showed the most significant effect on reducing the ROSLow cell subpopulation in HN-CICs (Fig. 5H; around 2% and Supplementary Fig. S7A). Next, we wanted to address whether SOD2 and/or CAT inhibition in combination with cisplatin treatment would reduce the cell viability in HN-CICs. As shown in Fig. 6A, the cell viability of CICs singly or combinatorially treated with 2-ME, 3-AT, and/or cisplatin was analyzed by MTT assay. Along with the reduction of ROSLow cell subpopulation in HN-CICs under triple treatment of 2-ME, 3-AT plus cisplatin (Fig. 5H), we also observed that the cell viability of the triple-treated HN-CICs was the most significantly diminished (left with around 35%) by MTT assay (Fig. 6A).

Finally, to further examine whether pharmacologic modulation of ROS levels contributed to cell death in HN-CICs, SAS sphere cells were singly or combinatorially treated with 2-ME, 3-AT, or cisplatin. The treated cells undergoing cell death was determined by co-stained with Annexin V and PI and examined by flow cytometry. Single treatment of 2-ME or 3-AT caused a slight increase in cell death of HN-CICs. In addition, combined treatment with 2-ME or 3-AT sensitized the cytotoxicity of cisplatin treatment in HN-CICs. Moreover, triple treatment with 2-ME and 3-AT plus cisplatin was the most effective and induced around 45% of the cell population undergoing cell death (Fig. 6B and Supplementary Fig. S7B). Together, these data demonstrate the importance of antioxidant defense to maintain the low ROS level, cell viability, and chemosensitivity of HN-CICs.

**Antioxidant ability is required to maintain the stemness properties and malignancy of HN-CICs**

To further evaluate whether the antioxidant ability is important to sustain the stemness properties of HN-CICs, the SAS sphere cells were treated with 2-ME, 3-AT, or cisplatin alone or in combination. As shown in Fig. 6C, the sphere cell singly treated with 2-ME or 3-AT displayed decreased expression of “cancer stemness” proteins (Oct-4 and Nanog). In opposite, we observed that sphere cell singly treated with cisplatin showed...
**A**

Cell viability (%) as a function of cisPt concentration (µmol/L) for OECM1-P, OECM1-S, SAS-P, and SAS-S cell lines.

**B**

Histograms showing ROS (ROS+) cell counts for SAS-S at cisPt concentrations of 0, 5, 10, and 20 µmol/L.

**C**

Histograms showing ROS (DCFDA+) cell counts for control and cisPt-treated SAS-S cell lines.

**D**

Histograms showing ROS (DCFDA+) cell counts for SAS-P and SAS-cisPtR cell lines.

**E**

Heat maps showing ALDH+ cells for different treatments (BAAA and BAAA+DEAB).

**F**

Diagram illustrating the mRNA upregulation in SAS-S and OECM1-S compared to SAS-P and OECM1-P (SOD2, CAT, PRDX3).

**G**

RT-PCR analysis of SOD2, CAT, PRDX3, and GAPDH expression levels in SAS-P, SAS-S, OECM1-P, and OECM1-S.

**H**

Table showing ROS (DCFDA+) cell counts for SAS-S treated with cisPt, 2ME, and 3AT.
higher protein levels of Oct-4 and Nanog but did not affect the expression of epithelial differentiation marker, cytokeratin 18 (CK-18) and Involucrin (Fig. 6C–E and Supplementary Fig. S7C). However, pharmacologic and genetic inhibition of SOD2 or catalase caused the increase of CK18+ subpopulation cells but the decreased expression of CIC marker CD133 in HN-CICs (Fig. 6D, Supplementary Fig. S8B and S8C). In addition, the sphere/anchorage-independent colony formation abilities of HN-CICs under genetic inhibition of SOD2 or catalase were also significantly abolished (Supplementary Fig. S8D and S8E). Interestingly, HN-CICs undergoing pharmacologic or genetic inhibition of catalase rather than inhibition of SOD2 displayed a more potent efficiency to cause the cell differentiation (Fig. 6D; 3-AT, 40%; 2-ME, 20%; Fig. 6E and Supplementary Fig. S8B). Nevertheless, the triple treatment of 3-AT, 2-ME plus cisplatin showed the most potential to enhance the CK18-positive cells (Fig. 6D; around 56% and Fig. 6E). In the mean times, triple treatment of 3-AT, 2-ME plus cisplatin significantly inhibited the sphere formation ability of HN-CICs, whereas relatively larger size spheres were observed from single cisplatin-treated HN-CICs (Fig. 6F).

We next sought to determine whether inhibition of the activity of ROS scavenger enzymes could attenuate the malignancy of HN-CICs both in vitro and in vivo. As shown in Fig. 6G, the anchorage-independent growth abilities of SAS sphere cells under triple treatment were significantly abolished by treatment of 3-AT, 2-ME plus cisplatin to SAS sphere cells or SAS-cisPtR cells significantly reduced the tumor volumes by xenograft transplantation assay (Fig. 6H and I). Overall, combined treatment with 2-ME and 3-AT reduced the self-renewal ability of HN-CICs, and sensitized the in vitro cytotoxicity mediated by cisplatin treatment on HN-CICs.

Catalase has been reported to be highly correlated with tumor malignant grade (36). We therefore proceeded to evaluate whether overexpression of catalase could enhance stemness properties. Treatment of SAS sphere cells with PEG-CAT displayed not only elevated expression of catalase activity but also the increased percentage of ROSlow cells (Supplementary Fig. S9A and S9B). Furthermore, we demonstrated that catalase overexpression also resulted in increased expression of CIC markers (memGrp78, CD44, and ALDH activity). (Supplementary Figs. S9C, S9D, and S10A). To further understand whether treatment of cisplatin, 3-AT or 2-ME can cause significant cytotoxicity to normal stem cells, the hematopoietic stem cells (HSC) were first treated with the above drugs and subjected to MTT assay, respectively. We observed that single treatment of cisplatin or 2-ME decreased the cell viability of HSC cells. However, there was no significant inhibition of cell viability on 3-AT–treated HSC cells (Supplementary Fig. S11).

Discussion

Patients with HNSCC are still very likely to relapse within months after therapy (37) that may be because conventional treatments cannot efficiently eliminate CICs, which are involved in the tumor progression, metastasis, and chemoresistance (2). Most of the anticancer drugs kill cancer cells by induced ROS generation, but prolonged treatment with the drugs results in reduced ROS level as a result of therapy resistance (38, 39). Caraglia and colleagues (40) provide evidence that the determination of oxidative stress status could be a marker of drug efficacy in patients with cancer. Thus, we hypothesized CICs are resistant to therapies due to their lower intracellular ROS content compared with the differentiated cancer cells. Moreover, understanding the relationships between ROS and drug resistance of CICs is important to improving the efficacy for future chemotherapies.

In the present study, we show that HN-CICs contain lower concentrations of ROS than parental cancer cells. Consequently, cell subpopulations, including ROSlow, ROSMedi, and ROShigh with differential ROS level, were isolated. Notably, ROSlow cancer cells are closely associated with CD133, memGrp78, Glut3, and ALDH1 cells (Fig. 1). We observed that the ROSlow cells displayed a sphere-growing phenotype; in contrast, both the ROSMedi and ROShigh cells grew as an adherent phenotype under the same culture condition (Fig. 2). Furthermore, ROSlow HN-CIC cells displayed CIC properties in comparison with ROSMedi and ROShigh subpopulation cells. Furthermore, cell-cycle studies indicated that ROSlow cells existed in lower Ki-67 activity (Fig. 3). Importantly, an in vivo nude mice model demonstrates that ROSlow population possessed high tumorigenic potential (Fig. 4). In addition, HN-CICs seem able to regulate ROS to exhibit chemoresistance by increasing production of antioxidant genes (Fig. 5). Pharmacologic depletion of ROS scavengers in CICs reduced their clonogenicity and resulted in chemosensitization to cisplatin both in vitro and in vivo (Fig. 6). Collectively, our data first demonstrated the crucial role of low ROS level for the tumorigenicity and chemoresistance of HN-CICs. In addition, distinct
Figure 6. Combined treatment with ROS scavenger inhibitors and cisplatin diminished the cell viability, the sphere formation ability and anchorage-independent growth, and enhanced the cell death and the differentiation ability of HN-CICs. SAS sphere cells were either singly treated with cisplatin or cotreated with ROS scavenger inhibitors (15 μmol/L 2-ME or 25 mmol/L 3-AT) for 72 hours. Afterward, the cell viability (A) and the cells undergoing cell death (B) caused by the drug treatment were further analyzed. For cell viability analysis, the drug-treated SAS sphere cells were further examined by MTT assay (see Materials and Methods). To evaluate the cells undergoing cell death, the drug-treated SAS sphere cells were stained with Annexin V plus PI and then examined by flow cytometry. C, expression of pluripotent stemness proteins (Oct4 and Nanog) in SAS-P-, SAS-S-, cisplatin-treated SAS, 2ME-treated, and 3AT-treated cells was determined by immunoblot analyses. D, the CK18-positive cells with the same treatment was determined by staining drug-treated cells with CK18 antibody and then examined by flow cytometry. (Continued on the following page.)
subpopulation of cells with differential intracellular ROS level in HNSCC exhibit diverse proliferative activity, CIC properties and chemoresistance.

Cells containing ROS-mediated high chemically reactive byproducts are implicated in stress and disease (41). Increasing evidence suggests that low levels of ROS are critical for maintaining stemness properties, where high levels of ROS effectively shut down self-renewal and confer potent capacity for stem cell differentiation (12, 42). In addition, CICs have similar redox properties as normal stem cell (43). Diehn and colleagues FoxO1 (16) have reported that breast CICs have a unique mechanism that protects themselves from ROS through increased antioxidant defenses and unique redox-dependent effects on tumor radioresistance. They also found that the breast CIC-enriched population is associated with genes involved in glutathione synthesis, including Gclm, Gss, and FoxO1. For glioblastoma, it has been reported that glioblastoma stem cells are assumed to constitute a radio-resistant fraction by HIF2α-mediated ROS status (33, 44). However, a relationship between ROS and chemoresistance property in HN-CICs remains elusive. In the present study, we demonstrated that lower ROS levels in HN-CIC enrichment is associated with increased expression of ROS scavenger such as catalase and SOD2. Pharmacologic depletion of ROS scavengers (SOD2 and/or catalase) in CICs markedly enhanced the cytotoxicity of cisplatin (Fig. 6). Notably, it is evident that catalase and SOD2 has been implicated in chemotherapy resistance of cancer cells (15, 45). On the basis of these findings, we proposed that different CSCs in diverse antioxidant systems have conserved this attribute, which probably helps protect their genomes from ROS-mediated damage. Previous studies also show that signaling molecules

![Figure 7. Schematic depicts physiologic features of ROSLow, ROSHigh, and ROSMedi cells related to chemoresistance, stemness properties, tumorigenicity, proliferative activity, etc. Our results (see contexts) indicate that ROSLow cells are in a quiescent state, and possess high tumorigenicity and enhanced stemness properties that may result in the chemoresistance of CICs to chemotherapy. On the other hand, ROSHigh cells are actively proliferate and more sensitive to therapy and differentiation. Furthermore, the ROSMedi cells exhibit more differentiation and nontumorigenicity.](image)

<table>
<thead>
<tr>
<th>Stemness</th>
<th>ROSLow</th>
<th>ROSMedi</th>
<th>ROSHigh</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quiescent</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Tumorigenicity</td>
<td>+++</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Differentiation</td>
<td>–</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Chemoresistance</td>
<td>+++</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

(Continued.) E, protein level of epithelial differentiation markers, CK18 and involucrin in drug-treated cells was assessed by Western blot analysis. F, single-cell suspension of SAS sphere cells was treated with cisplatin or cotreated with ROS scavenger inhibitors (2-ME and/or 3-AT) for 72 hours, and the sphere formation ability of drug-treated cells was examined (see Materials and Methods). Arrows, the sphere cells. G, in addition, the abovementioned SAS sphere cells were also plated onto soft agar for 12 days, and the colony formation ability of drug-treated SAS sphere cells was examined (see Materials and Methods). Data, means ± SD of triplicate samples from three experiments (**P < 0.005). Representative images of tumors generated on the recipient nude mice, which were inoculated with drug-treated SAS sphere (H) and SAS cisPtR (I) cells into the subcutaneous space, were photographed (white arrows, control group; black arrows, drug-treated group). Tumor volume was also measured and recorded after inoculation of drug-treated SAS sphere (H) and SAS cisPtR (I) cells in nude mice.
such as FoxOs, APE1/Ref-1, Nrf2, ATM, HIFs, p38, and p53 are involved in the regulation of stem cell self-renewal and differentiation through modulation in antioxidant enzyme systems (11). Therefore, future research delineating the details of what ROS signaling molecules are essential to maintaining stemness properties of CICs in these different cell types are remained to be determined.

CICs in colon, breast, and ovaries have been shown to demonstrate the ability to maintain a quiescent state to evade therapy (46–48). In addition, Dey-Guha and colleagues (49) report that rapidly proliferating cancer cells can produce “G0-like” progeny through asymmetric division, which are enriched following chemotherapy in breast cancer. These G0 phase cells show lower intracellular ROS level and exhibit suppressing AKT expression. Herein, we also found that low endogenous ROS status of HNSCCs maintains the quiescent state of CICs. Surprisingly, we observed ROSHigh cells exhibit the high proliferation index (Fig. 3E and F). Recently, many reports demonstrate that higher ROS state is essential for proliferation of stem/progenitor cells (14, 50). For example, ROS can play roles as second messengers in tightly neural stem cell proliferation and survival by driving PI3K/AKT signaling (24). In addition, it is evident that ROS generation is essential for K-ras–mediated cell proliferation and tumorigenesis in lung cancer (51). On the basis of these findings, we proposed that CIC-enriched populations are partially differentiated due to persistent ROS redox stress on the basis of tumor microenvironment changes, which lead to a heterogeneous mixture of CICs and non-CICs in the tumor. It would be of interest to determine the regulations of these signaling pathways of ROSLow and ROSHigh HN-CICs, respectively. These studies also suggest that combination of inhibitors for ROSLow and ROSHigh regulator of the signaling pathway might be more effective compared with blockade of single regulating HN-CICs.

Most conventional anticancer drugs such as cisplatin and 5-fluorouracil are preferentially toxic to proliferating cells, decreases tumor size (52). Herein, we have also confirmed that long-term treatment of cisplatin can enhance the ROSLow cells of CIC properties, and make them prone to survive (Fig. 5D and E). Furthermore, combinatorial treatment of scavenger inhibitors for ROSLow and conventional anticancer drugs reduced the self-renewal ability and survival in HN-CICs (Fig. 5 and 6). In the mean times, it is effective to target the proliferative ROSHigh cells by long-term treatment of cisplatin (Fig. 5C). Therefore, it will be reasonable that cotreatment with an ROSLow inhibitor along with an ROSHigh inhibitor as a chemotherapeutic regimen may improve the future treatment of HNSCCs.

Together, this research shows that HN-CICs contain distinct subpopulation cells, and the elevated ROSLow cells in HN-CICs mainly contribute to tumor progression and chemo-resistance (Fig. 7). Clinical therapies could perhaps be optimized by overcoming low ROS levels, and identification of regulatory ROS level mechanisms in CICs may be a useful prognostic factor for patients with HNSCC.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: Y.-S. Chen, C.-Y. Huang, J.-F. Lo
Development of methodology: C.-W. Chang, Y.-S. Chen, J.-F. Lo
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y.-S. Chen, S.-H. Chou, C.-C. Yang, C.-Y. Huang, J.-F. Lo
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.-W. Chang, Y.-S. Chen, C.-C. Yang, C.-Y. Huang, J.-F. Lo
Writing, review, and/or revision of the manuscript: C.-W. Chang, Y.-S. Chen, C.-Y. Huang, J.-F. Lo
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y.-S. Chen, C.-L. Han, Y.-J. Chen, C.-Y. Huang, J.-F. Lo
Study supervision: Y.-S. Chen, Y.-J. Chen, C.-Y. Huang, J.-F. Lo

Acknowledgments
The authors thank Dr. K-W Chang (Department of Dentistry, National Yang-Ming University) for providing critical comments on the article.

Grant Support
This study was supported by grants from the National Science Council (NSC 101-2314-B-039-042-MY3, 102-2314-B-039-042-MY3, 102-2314-B-039-042-MY3, and 102-2314-B-039-042-MY3), and Ministry of Education, Aim for the Top University Plan, National Yang-Ming University (101ACT133 and 102AC-TC14).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 4, 2014; revised July 30, 2014; accepted August 19, 2014; published OnlineFirst September 12, 2014.

References
3. Moore N, Lyle S. Quiescent, slow-cycling stem/progenitor cells (14, 50). For example, ROS can play roles as second messengers in tightly neural stem cell proliferation and survival by driving PI3K/AKT signaling (24). In addition, it is evident that ROS generation is essential for K-ras–mediated cell proliferation and tumorigenesis in lung cancer (51). On the basis of these findings, we proposed that CIC-enriched populations are partially differentiated due to persistent ROS redox stress on the basis of tumor microenvironment changes, which lead to a heterogeneous mixture of CICs and non-CICs in the tumor. It would be of interest to determine the regulations of these signaling pathways of ROSLow and ROSHigh HN-CICs, respectively. These studies also suggest that combination of inhibitors for ROSLow and ROSHigh regulator of the signaling pathway might be more effective compared with blockade of single regulating HN-CICs.

Most conventional anticancer drugs such as cisplatin and 5-fluorouracil are preferentially toxic to proliferating cells, decreases tumor size (52). Herein, we have also confirmed that long-term treatment of cisplatin can enhance the ROSLow cells of CIC properties, and make them prone to survive (Fig. 5D and E). Furthermore, combinatorial treatment of scavenger inhibitors for ROSLow and conventional anticancer drugs reduced the self-renewal ability and survival in HN-CICs (Fig. 5 and 6). In the mean times, it is effective to target the proliferative ROSHigh cells by long-term treatment of cisplatin (Fig. 5C). Therefore, it will be reasonable that cotreatment with an ROSLow inhibitor along with an ROSHigh inhibitor as a chemotherapeutic regimen may improve the future treatment of HNSCCs.

Together, this research shows that HN-CICs contain distinct subpopulation cells, and the elevated ROSLow cells in HN-CICs mainly contribute to tumor progression and chemo-resistance (Fig. 7). Clinical therapies could perhaps be optimized by overcoming low ROS levels, and identification of regulatory ROS level mechanisms in CICs may be a useful prognostic factor for patients with HNSCC.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: Y.-S. Chen, C.-Y. Huang, J.-F. Lo
Development of methodology: C.-W. Chang, Y.-S. Chen, J.-F. Lo
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y.-S. Chen, S.-H. Chou, C.-C. Yang, C.-Y. Huang, J.-F. Lo
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.-W. Chang, Y.-S. Chen, C.-C. Yang, C.-Y. Huang, J.-F. Lo
Writing, review, and/or revision of the manuscript: C.-W. Chang, Y.-S. Chen, C.-Y. Huang, J.-F. Lo
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y.-S. Chen, C.-L. Han, Y.-J. Chen, C.-Y. Huang, J.-F. Lo
Study supervision: Y.-S. Chen, Y.-J. Chen, C.-Y. Huang, J.-F. Lo

Acknowledgments
The authors thank Dr. K-W Chang (Department of Dentistry, National Yang-Ming University) for providing critical comments on the article.

Grant Support
This study was supported by grants from the National Science Council (NSC 101-2314-B-039-042-MY3, 102-2314-B-039-042-MY3, and 102-2314-B-039-042-MY3), and Ministry of Education, Aim for the Top University Plan, National Yang-Ming University (101ACT133 and 102AC-TC14).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 4, 2014; revised July 30, 2014; accepted August 19, 2014; published OnlineFirst September 12, 2014.

10. Gupta SC, Hevia D, Patichva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of...


Distinct Subpopulations of Head and Neck Cancer Cells with Different Levels of Intracellular Reactive Oxygen Species Exhibit Diverse Stemness, Proliferation, and Chemosensitivity


Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-14-0626

Supplementary Material
Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2014/09/13/0008-5472.CAN-14-0626.DC1

Cited articles
This article cites 51 articles, 12 of which you can access for free at: http://cancerres.aacrjournals.org/content/74/21/6291.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/74/21/6291.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.